AstraZeneca plc (LON:AZN)‘s stock had its “neutral” rating reissued by investment analysts at Credit Suisse Group in a research note issued to investors on Monday. They currently have a GBX 4,700 ($60.70) price objective on the biopharmaceutical company’s stock. Credit Suisse Group’s price target would suggest a potential downside of 4.57% from the stock’s previous close.
Several other research firms have also issued reports on AZN. Morgan Stanley restated an “overweight” rating and issued a GBX 5,600 ($72.32) price objective on shares of AstraZeneca plc in a research note on Friday, June 23rd. UBS AG set a GBX 5,150 ($66.51) price objective on AstraZeneca plc and gave the company a “neutral” rating in a research note on Tuesday, June 27th. Shore Capital restated a “hold” rating on shares of AstraZeneca plc in a research note on Wednesday, June 21st. Barclays PLC restated an “overweight” rating and issued a GBX 6,000 ($77.49) price objective on shares of AstraZeneca plc in a research note on Monday, June 5th. Finally, J P Morgan Chase & Co restated a “neutral” rating on shares of AstraZeneca plc in a research note on Monday, June 5th. Three analysts have rated the stock with a sell rating, nine have issued a hold rating and ten have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of GBX 4,963.82 ($64.11).
Shares of AstraZeneca plc (LON:AZN) opened at 4925.00 on Monday. AstraZeneca plc has a 12-month low of GBX 3,996.00 and a 12-month high of GBX 5,520.00. The firm’s market cap is GBX 62.35 billion. The firm has a 50-day moving average price of GBX 4,580.96 and a 200-day moving average price of GBX 4,880.60.
In related news, insider Nazneen Rahman bought 39 shares of the stock in a transaction that occurred on Thursday, July 27th. The stock was acquired at an average cost of GBX 4,370 ($56.44) per share, with a total value of £1,704.30 ($2,201.08).
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.